Footnotes:

^*The AMPLIFY clinical trial was a randomised, double-blind, non-inferiority trial in 5,395 patients with acute VTE. Efficacy analyses were based on ITT population for whom the outcome status at 6 months was documented. All safety analyses included data obtained from patients during study treatment, defined as the time from administration of the first dose until 48 hours after the last dose was administered.^1
†The primary efficacy endpoint was the incidence of the adjudicated composite of recurrent symptomatic venous thromboembolism VTE or death from any cause related to venous thromboembolism.¹ Recurrent venous thromboembolism included fatal or non-fatal PE and DVT.^1
‡The primary safety endpoint was the incidence of an adjudicate of major bleeding.¹ For patients who had more than one event, only the first was counted.^1
§The secondary safety endpoint was the composite of major or CRNM bleeding events.¹ For patients who had more than one event, only the first was counted.^1
¶This link is to a third-party site unaffiliated with the Pfizer / BMS Alliance. Please abide by the terms of use of the site.

CI = Confidence Interval   CRNM = Clinically Relevant Non-Major Bleeding   DVT = Deep Vein Thrombosis   ITT= Intention-to-Treat N = Total number of patients in the ELIQUIS group or the enoxaparin / warfarin group   n = Number of patients with event   PE = Pulmonary Embolism   RR = Relative Risk   VTE = Venous Thromboembolism

References:

1. Agnelli G et al. N Engl J Med 2013; 369: 799–808.
2. ELIQUIS^® (apixaban) Summary of Product Characteristics.